Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Aug 12, 2014 11:00 AM - Aug 12, 2014 12:30 PM

(Eastern Standard Time)

Online

Seven-Part Series on Pediatric Drug Development - Part V: Technical Development: Pediatric Formulations

Speakers

Klaus  Rose, MD, MS

Klaus Rose, MD, MS

Chief Executive Officer, klausrose Consulting, Switzerland

Klaus Rose, a German MD with postgraduate degrees in General & Pharmaceutical Medicine, was 20 years with Big Pharma. In 2001, he became Global Head Pediatrics at Novartis & 2005 at Roche ; CEO of klausrose Consulting since 2011. He advises on pediatric drug development and FDA/EMA pediatric requirements. Private interests: languages, classical guitar, cooking, wine & gardening

Daniel  Bar-Shalom

Daniel Bar-Shalom

Associate Professor, Department of Pharmacy, University of Copenhagen, Denmark

Siri  Wang

Siri Wang

Scientific Director; PDCO delegate, Norwegian Medical Products Agency, Norway

Siri Wang is Scientific Director at the Norwegian Medical Products Agency (NOMA). She is pharmacist by education and holds a PhD in pharmacology from University of Oslo. She has worked in hospital pharmacy for 15 years, mainly as counseling/clinical pharmacist, specifically involved in paediatric and geriatric medicine. Since 2007 Siri has been delegate to the Paediatric Committee (PDCO) at EMA. She was chair of PDCO’s Formulation Working Group from 2008 until 2013 and chair of CMDh/EMA Working Party on Paediatric Regulation from 2019 until 2023. Siri has been at NOMA full time since 2010 and has in her role a particular focus on paediatric medicines, covering the life cycle perspectives from development to actual access for children.

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.